Tamia Nguyen
YOU?
Author Swipe
View article: Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer
Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer Open
View article: Enhanced Disease Detection of Hairy Cell Leukaemia Through Next‐Generation Sequencing Based <i>BRAF</i><sup>V600E</sup> and Phased Variant Analysis
Enhanced Disease Detection of Hairy Cell Leukaemia Through Next‐Generation Sequencing Based <i>BRAF</i><sup>V600E</sup> and Phased Variant Analysis Open
Introduction Longitudinal disease assessment by molecular techniques is not routine in hairy cell leukaemia (HCL). Combining BRAF V600E and other genomic targets through next‐generation sequencing (NGS) with phased variant analysis is a no…
View article: CD34‐TdT‐B‐ALL masquerading as Burkitt lymphoma
CD34‐TdT‐B‐ALL masquerading as Burkitt lymphoma Open
A 23-year-old female presented with widespread petechiae and oral mucosal bleeding. There was no palpable lymphadenopathy or hepatosplenomegaly. Complete blood count included haemoglobin 77 g/L (normal 115–155), white cell count 20.4 × 109…
View article: Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC) Open
PURPOSE A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. METHODS Patients with either MRD (≥1 lo…
View article: Persistence of <i>UBTF</i> tandem duplications in remission in acute myeloid leukaemia
Persistence of <i>UBTF</i> tandem duplications in remission in acute myeloid leukaemia Open
UBTF tandem duplications are recurrent in adult and paediatric acute myeloid leukaemia and have been reported to be associated with a poor prognosis. Co‐mutations in WT1 and FLT3 are common while morphological dysplasia is frequent. The ro…
View article: Variant acute promyelocytic leukaemia with novel <i>NAB2::RARA</i> fusion shows clinical all‐<i>trans</i> retinoic acid and arsenic trioxide sensitivity
Variant acute promyelocytic leukaemia with novel <i>NAB2::RARA</i> fusion shows clinical all‐<i>trans</i> retinoic acid and arsenic trioxide sensitivity Open
Acute promyelocytic leukaemia (APL) is characterised by reciprocal translocation between the promyelocytic leukaemia (PML) gene at chromosome 15q24 and the retinoic acid receptor alpha (RARA) gene at chromosome 17q21. The resulting PML::RA…
View article: Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia Open
The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with previously treated chronic lymphocytic leukemia (CLL). However, despite continuous daily treatment, leukemia recurs in most patients. To investigate the…
View article: Supplementary Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Supplementary Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia Open
Supplementary Material
View article: Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia Open
The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with previously treated chronic lymphocytic leukemia (CLL). However, despite continuous daily treatment, leukemia recurs in most patients. To investigate the…
View article: Supplementary Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Supplementary Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia Open
Supplementary Material
View article: Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors Open
The genomic landscape of resistance to targeted agents (TAs) used as monotherapy in chronic lymphocytic leukemia (CLL) is complex and often heterogeneous at the patient level. To gain insight into the clonal architecture of acquired genomi…
View article: Clonal hematopoiesis, myeloid disorders and <i>BAX</i>-mutated myelopoiesis in patients receiving venetoclax for CLL
Clonal hematopoiesis, myeloid disorders and <i>BAX</i>-mutated myelopoiesis in patients receiving venetoclax for CLL Open
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated…
View article: Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing
Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing Open
View article: BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax Open
Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymphocytic leukemia (CLL). Results of prospective clinical trials demonstrate the efficacy of venetoclax to salv…
View article: Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax Open
The BCL2 inhibitor venetoclax has complete response rates of up to 50% in chronic lymphocytic leukemia patients, but secondary resistance reflecting acquired mutations in BCL2 can lead to treatment failure. Blombery et al report that an un…
View article: Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma Open
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
View article: PS1308 TARGETING T‐CELL RECEPTOR SIGNALING PATHWAY BY DASATINIB IN RELAPSED/REFRACTORY ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA
PS1308 TARGETING T‐CELL RECEPTOR SIGNALING PATHWAY BY DASATINIB IN RELAPSED/REFRACTORY ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA Open
Background: Angioimmunoblastic T‐cell lymphoma (AITL) is an intractable T‐cell lymphoma. The recurrent hotspot (p.Gly17Val) mutations in RHOA encoding a small GTPase, together with the loss‐of‐function mutations in TET2 encoding an epigene…